ESR1 and breast cancer: Recently, Wolfson and colleagues (46) demonstrated that tamoxifen and 4-hydroxytamoxifen sensitize breast cancer cells to natural killer (NK) cell-mediated killing as immunomodulatory agents regardless of estrogen receptor expression.